Acadia Pharmaceuticals Receives EU Endorsement for Daybu in Rett Syndrome
Acadia Pharmaceuticals (ACAD) gained ~13% after the European Medicines Agency's expert panel endorsed marketing authorization for its drug, Daybu, to treat Rett syndrome. This regulatory progress could enhance investor confidence and potentially expand the company’s market presence.
Tickers: $ACAD
Topics: EMA pharmaceuticals Rett syndrome